The only FDA item in today's respiratory sweep is a supplement dated 23 September to AbbVie's application for Ozurdex (NDA022315). Ozurdex is a dexamethasone implant injected into the eye for macular oedema and uveitis; the sweep picked it up because it contains dexamethasone. The record does not say what the supplement covers.
It does not affect systemic or inhaled corticosteroid use in lung disease, and there is no respiratory approval or safety action to report today.
- No change to respiratory prescribing
- No new safety communication on corticosteroids
Why it matters
It confirms there was no respiratory regulatory action in today's sweep.
Don't overread it
A supplement to an ophthalmic implant's application says nothing about systemic or inhaled steroids.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free